Distinguished leaders of drugging gene control in both academia and industry were brought together to further the understanding of diseases of gene regulation, especially RNA and chromatin biology, at the 1st Annual THINC Symposium held May 31, 2018 - June 1, 2018. The unique talks and diverse expertise were met with great enthusiasm by trainees, researchers, and anyone interested in gene regulation and therapeutics. Q&A sessions after each talk were engaging, allowing participants to interact with prominent speakers on the themes of RNA & Disease, Academic Drug Discovery, and Drugging Transcription .
Speaking on RNA & Disease were Huda Zoghbi, M.D. (Baylor College of Medicine), Eric Wang, Ph.D. (University of Florida), Silvia Buonamici, Ph.D. (H3 Biomedicine), and Noreen Rizvi, Ph.D. (Merck & Co; Siemens Healthineers). Speaking on Academic Drug Discovery were Michael Foley, Ph.D. (Tri-Institutional Therapeutics Discovery Institute), Casey Cunningham, M.D. (Santé Ventures), Rajesh Chopra, Ph.D. (ICR London), and Arthur T. Sands, M.D., Ph.D. (Nurix). Speaking on Drugging Transcription were H. Courtney Hodges, Ph.D. (Baylor College of Medicine), Paul Clarke, Ph.D. (ICR London), Louis Chesler, M.D., Ph.D. (ICR London), and Richard A. Young, Ph.D. (Whitehead Institute, MIT).